Anatomy hub
Knee: Options and What the Evidence Actually Shows
Osteoarthritis, meniscus injury, and ligament problems dominate knee searches. Here is the standard ladder of care — and where autologous cell approaches enter the conversation.
Where are you in this?
Same page, different emphasis. Now-path goes to the ladder and providers; ahead-path goes to banking younger cells.
Anatomy and clinical context
The knee is a weight-bearing hinge with cartilage, menisci, ligaments, and synovium that all age and fail differently. Pain is common; the diagnosis behind it is not always the same.
Most patients work through activity modification, physical therapy, bracing, oral meds, and image-guided injections before considering surgery. Regenerative injectates are often discussed in that middle band — after conservative care, before or instead of arthroplasty in selected cases.
The standard ladder of care
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs inside that conversation — not above it.
- 1
Conservative care
Activity modification, physical therapy, weight management, bracing, and oral analgesics or anti-inflammatories.
- 2
Injections
Corticosteroid, hyaluronic acid, PRP, and orthobiologic injectates including same-day bone marrow or adipose-derived products when a physician recommends them.
Autologous cell approaches enter here — dose and donor age are what change the conversation.
- 3
Surgery
Arthroscopy for selected mechanical problems; osteotomy or partial/total knee replacement when joint disease is advanced.
Already getting a procedure?
Scheduled for a bone-marrow or fat-based procedure? The collection is the hard part — and yours is already happening. Ask your physician about banking the remainder of your sample with Forever Labs: same draw, no extra procedure, and the youngest cells you'll ever have from this day forward stay preserved for whatever comes next.
Guide
The Honest Guide to Stem Cells for Knee OA
The ladder, the honest evidence read, and the availability map — packaged from this page. Email gates the guide; nothing in the evidence section is softened to earn it.
Availability
Where this procedure is available
Availability requires both an authorizing state statute and a Forever Labs network physician. Status updates when we publish a provider in Payload — no code change required.
Available now
Florida
Orthopedic authorizationSB 1768 · Ch. 2025-185; Fla. Stat. §§ 458.3245, 459.0127
- Dr. Moises Irizarry-Roman, MD · Miami, Florida
- Dr. Tad DeWald, MD · Miami, Florida
- Dr. Joshua Hackel, MD · Gulf Breeze, Florida
Law open — network coming
Tennessee
HB 2246 · Tenn. Code Ann. Titles 63 & 68 (as amended)
Forever Labs network recruitment in progress — no committed quarter yet
Rulemaking still pending
Wyoming
SF 0048 — Stem Cell Freedom Act · W.S. §§ 35-4-1101 through 35-4-1106
Forever Labs network recruitment in progress — no committed quarter yet
Physician must be listed on the Board of Medicine registry
Get notified the moment your state opens
Self-select by geography. We email you when the statute and network status changes — not a newsletter.
Pending legislation
Arizona
SB 1214 — Bill still pending; definition would expressly cover culture-expanded cells
Different pathway
These states have regenerative-medicine laws, but not Florida-style orthopedic authorization. Labeled with their actual scope.
Review-board pathway
Montana
SB 535 — Phase 1 safety data + review-board approval required; not condition-specific
Right-to-try
Texas
HB 810 + HB 5147 — Restricted to severe chronic or terminal illness
Right-to-try
Mississippi
Stem cell investigational access — Right-to-try style; not a general orthopedic authorization
Birth tissue only
Utah
SB 199 / SB 275 — Allogeneic birth tissue only — not autologous MSC banking
Not in one of these states?
Banking and shipping are nationwide. Your cells can be shipped to your physician, but the procedure itself has to be arranged with your doctor first.
Browse the full provider networkVerified as of July 31, 2026. Statute claims cite primary sources. Forward-looking network quarters are Forever Labs targets, not legislative promises. Therapies described here are not FDA-approved.
Evidence
Where cell therapy fits
Large controlled trials of same-day, minimally manipulated products in knee OA have often landed at parity with cheaper comparators. That does not mean cells never help — it means dose and product type matter, and honest reading of the literature is part of good care.
- 2
- Randomized trials
- 2
- Expanded-cell approvals
- 440
- Largest trial (participants)
The honest read — Same-day products keep landing at parity. The approved products that show more are the expanded ones — which makes dose, not enthusiasm, the variable worth acting on. Receipts in the Evidence Room
- 01Parity with comparator
MILES (Mautner, Nature Medicine 2023) compared BMAC, umbilical tissue, and SVF to corticosteroid in knee OA: none beat steroid at one year; MRI scores did not improve.
SourceMILES - 02Parity with comparator
Shapiro (AJSM 2017) compared BMAC to saline in contralateral knees — no difference on primary endpoints.
SourceShapiro 2017 - 03Dose-enabled pathway
Culture-expanded products such as Cartistem (Korea) and Stempeucel (India) illustrate pathways where therapeutic dose is engineered — the argument for banking younger cells and expanding later.
The sources
Both directions, cited plainly — the trials that found no advantage and the approvals that show what engineered dose looks like.
- Randomized trialn = 440
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
- Randomized trial
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
- Regulatory approvalSouth Korea
Cartistem
Approved product (Korea) · Regulatory approval (2012)
Culture-expanded allogeneic MSC product approved in Korea with structural signal in cartilage repair settings.
- Regulatory approvalIndia
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
For physicians
Treating Knee? See how practices in our network offer banking and dose.
Reviewed by Tom Nabity, MD. Last reviewed August 26, 2026.
You are your own best donor
The cells you'd want later are the ones you have today.
Mesenchymal stem cells are the population regenerative medicine studies most, and yours are more numerous and more vigorous now than they will be a decade from now. Banking is how today's cells stay available to your physician later. Why dose and donor age are the variable
Your cells, your biology.
Autologous means no donor, no waitlist, and no match required. What we store came from you and goes back only at your request.
Younger cells are more vigorous cells.
MSC counts and proliferative capacity decline with age. Bank at 35 and those cells stay available to the 55-year-old you.
One collection, a larger supply.
Culture expansion is how a single collection becomes more than a single vial. Dose is the variable separating the same-day trials that landed at parity from the expanded products approved abroad. Rolling out as our Florida cGMP lab comes online.
Ready when you and your physician decide.
Your cells stay in cryopreservation until you ask for them. What happens next is a conversation with your doctor — Forever Labs stores cells, it does not practice medicine.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.
